Group 1 - The concept of Helicobacter pylori has seen an increase of 1.93%, ranking 9th among concept sectors, with 62 stocks rising, including Rundu Co., Aosaikang, and Zhejiang Zhenyuan hitting the daily limit [1][2] - Leading gainers in the Helicobacter pylori sector include Laimei Pharmaceutical, Hanyu Pharmaceutical, and Te Yi Pharmaceutical, with increases of 8.48%, 6.41%, and 5.49% respectively [1] - The sector experienced a net inflow of 774 million yuan from main funds, with 49 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow, led by Hanyu Pharmaceutical with 166 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio are Rundu Co. at 42.20%, Zhejiang Zhenyuan at 29.25%, and ST Huluwa at 16.55% [3][4] - Hanyu Pharmaceutical had a trading volume of 165.89 million yuan with a net inflow ratio of 6.26%, while Rundu Co. had a trading volume of 144.66 million yuan [3][4] - The overall market performance shows a mixed trend, with some stocks like Zhijiang Biology, ST Suwu, and Dongfang Ocean experiencing declines of 6.08%, 5.02%, and 4.23% respectively [6][7]

Group 1: Robotics Sector - Several companies in the robotics sector have seen significant stock price increases, with Zhejiang Rongtai rising by 10.00%, Jujie Microfiber by 20.02%, and Houtai Co. by 10.01% [2][3] - Other notable mentions include Fuda Co. at 10.01%, Donggang Co. at 9.96%, and Junhe Co. at 9.99%, all attributed to the robotics theme [2] Group 2: Innovative Pharmaceuticals - The innovative pharmaceutical sector is experiencing a surge, with Lianhuan Pharmaceutical achieving 9.98% increase over eight consecutive trading days, and Wanbangde and Aosaikang both rising by 10.01% and 10.02% respectively [5][7] - Zhejiang Zhenyuan and Rundu Co. also reported first board appearances with increases of 9.98% and 10.03% respectively, driven by the innovative drug theme [5] Group 3: Performance Surprises - Over 57% of listed companies have reported positive performance forecasts for the first half of the year, with a nearly 70% increase in total net profit compared to the same period last year [8] - Companies like Dayilong and Huahong Technology have seen stock increases of 10.03% and 10.04% respectively, attributed to strong performance and market conditions [9] Group 4: Electric Vehicles - The automotive sector is thriving, with production and sales exceeding 15 million units in the first half of the year, marking a double-digit growth year-on-year [12] - Companies such as Zhejiang Liming and Tianlong Co. have reported stock increases of 9.98% and 10.00% respectively, linked to the automotive and chip sectors [13] Group 5: AI Applications - The AI application sector is gaining traction, with companies like Puyuan Information and Keri International seeing stock increases of 20.01% and 14.36% respectively, driven by advancements in AI infrastructure [24][23] Group 6: Digital Currency - The digital currency sector is witnessing increased attention, with over five cities mentioning stablecoins in recent discussions, leading to stock increases for companies like Jinshi Technology and Dongxin Peace [28][29]

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Core Points - Zhejiang Zhenyuan Co., Ltd. received an inquiry letter from Shenzhen Stock Exchange regarding its application for issuing shares to specific targets [1][2] - The company, along with relevant intermediaries, has conducted thorough research and updates on the issues raised in the inquiry letter and the fundraising prospectus [1][2] - The issuance of shares to specific targets is subject to approval from Shenzhen Stock Exchange and the China Securities Regulatory Commission [2] Summary by Sections - **Company's Actions** - The company received the inquiry letter on November 14, 2024, and has updated its fundraising prospectus accordingly [1] - The updated documents were disclosed on December 6, 2024, on the official information platform [1] - **Regulatory Approval** - The issuance of shares requires approval from both Shenzhen Stock Exchange and the China Securities Regulatory Commission [2] - There is uncertainty regarding the approval process and timeline for the issuance [2] - **Investor Communication** - The company will fulfill its information disclosure obligations based on the progress of the issuance [2] - Investors are advised to make cautious decisions and be aware of investment risks [2]

浙江震元股份有限公司 2024 年向特定对象发行股票募集说明书（申报稿） 证券简称：浙江震元 证券代码：000705 浙江震元股份有限公司 （注册地址：浙江省绍兴市稽山街道延安东路 558 号） 2024 年向特定对象发行股票 募集说明书 （申报稿） 保荐人（主承销商） （杭州市五星路 201 号） 二〇二五年六月 浙江震元股份有限公司 2024 年向特定对象发行股票募集说明书（申报稿） 声 明 本公司及全体董事、监事、高级管理人员承诺本募集说明书内容真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承 担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证 募集说明书中财务会计报告真实、完整。 中国证券监督管理委员会、深圳证券交易所对本次发行所作的任何决定或意 见，均不表明其对公司所发行证券的价值或者投资人的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益 ...

证券简称：浙江震元 证券代码：000705 关于浙江震元股份有限公司 申请向特定对象发行股票 审核问询函的回复(修订稿) 保荐机构（主承销商） 二零二五年七月 1-1 深圳证券交易所： 浙江震元股份有限公司（以下简称"公司"、"发行人"或"浙江震元"） 收到贵所于 2024 年 11 月 14 日下发的《关于浙江震元股份有限公司申请向特定 对象发行股票的审核问询函》（审核函〔2024〕120050 号）（以下简称"《问 询函》"），公司已会同浙商证券股份有限公司（以下简称"浙商证券"、"保 荐机构"）、上海市锦天城律师事务所（以下简称"发行人律师"）、天健会计 师事务所（特殊普通合伙）（以下简称"会计师"）进行了认真研究和落实，并 按照问询函的要求对所涉及的事项进行了资料补充和问题回复，现提交贵所，请 予以审核。 说明： 除非文义另有所指，本问询函回复中的简称与《浙江震元股份有限公司 2024 年向特定对象发行股票募集说明书》（以下简称"募集说明书"）中的释义具有 相同涵义。 本问询函回复的字体说明如下： | 问询函所列问题 | 黑体 | | --- | --- | | 对问询函所列问题的回复 | 宋体 | ...

上海市锦天城律师事务所 关于浙江震元股份有限公司 2024 年度向特定对象发行股票的 补充法律意见书（二） 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 补充法律意见书（二） 上海市锦天城律师事务所 关于浙江震元股份有限公司 2024 年度向特定对象发行股票的 补充法律意见书（二） 致：浙江震元股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江震元股份有限公司（以 下简称"发行人"或"公司"或"浙江震元"）的委托，并根据发行人与本所签订的《专 项法律服务合同》，作为发行人 2024 年度向特定对象发行股票（以下简称"本次 发行"）的特聘专项法律顾问。 本所根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）及《上市公司证券发行注册管理办法》 （以下简称"《注册管理办法》"或"《管理办法》"）等有关法律、法规、规章和 规范性文件的规定，就本次发行所涉有关事宜，于 2024 年 10 月 14 日出具了《上 海市锦 ...

浙商证券股份有限公司 关于浙江震元股份有限公司 2024 年向特定对象发行股票 之 发行保荐书 保荐人（主承销商） 二〇二五年六月 浙商证券股份有限公司 关于浙江震元股份有限公司 2024年向特定对象发行股票之发行保荐书 作为浙江震元股份有限公司（以下简称"浙江震元"、"发行人"或"公司"） 向特定对象发行股票的保荐人，浙商证券股份有限公司（以下简称"本保荐人"、 "保荐人"或"浙商证券"）及其指定的保荐代表人已根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《证券发行上市保荐业务管理办法》（以下简称"《保荐管理办法》"）、《上市公 司证券发行注册管理办法》（以下简称"《注册管理办法》"）等法律法规和中 国证监会及深圳证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制 订的业务规则、行业执业规范和道德准则出具本发行保荐书，并保证所出具文件 的真实性、准确性和完整性。 非经特别说明，本发行保荐书中所用简称均与募集说明书具有相同的含义。 一、本次证券发行基本情况 2、张鼎科：2008 年开始从事投资银行工作，负责或参与的项目有：中超电 缆、龙洲 ...

浙商证券股份有限公司 关于浙江震元股份有限公司 2024 年向特定对象发行股票 上市保荐书 浙商证券股份有限公司 保荐人（主承销商） 关于浙江震元股份有限公司 二〇二五年六月 之 2024年向特定对象发行股票之上市保荐书 作为浙江震元股份有限公司（以下简称"浙江震元"、"发行人"或"公司"） 向特定对象发行股票的保荐人，浙商证券股份有限公司（以下简称"本保荐人"、 "保荐人"或"浙商证券"）及其指定的保荐代表人已根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《证券发行上市保荐业务管理办法》（以下简称"《保荐管理办法》"）、《上市公司 证券发行注册管理办法》（以下简称"《注册管理办法》"）等法律法规和中国证监 会及深圳证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业 务规则、行业执业规范和道德准则出具本上市保荐书，并保证所出具文件的真实 性、准确性和完整性。 非经特别说明，本上市保荐书中所用简称均与募集说明书具有相同的含义。 一、发行人基本情况 | （一）发行人简介 | | --- | | 公司名称： | 浙江震元股份有限公司 | ...

| | | | 一、问题一………………………………………………………… 第1—9页 | | | --- | --- | | 二、问题二………………………………………………………… 第9—63页 | | | 三、问题三……………………………………………………… 第63—116页 | | | 四、问题四………………………………………………………第116—155页 | | | 五、附件…………………………………………………………第156—160页 | | | （一）本所营业执照复印件………………………………………… 第156页 | | | （二）本所执业证书复印件………………………………………… 第157页 | | | （三）本所从事证券服务业务备案完备证明材料………………… 第158页 | | | （四）签字注册会计师证书复印件………………………… 第 159—160 | 页 | 关于浙江震元股份有限公司 申请向特定对象发行股票的审核问询函中 有关财务事项的说明 天健函〔2025〕672 号 深圳证券交易所： 由浙商证券股份有限公司转来的《关于浙江震元股份有限公司申请向特定对 象发行股票的审核问询函》（审核函〔2 ...